Intervention Protocol

Antibody immunosuppression for pancreas and kidney-pancreas transplant recipients

  1. Luit Penninga1,*,
  2. Angela C Webster2,3,4,
  3. Martin Egfjord5,
  4. Daniel A Steinbrüchel6,
  5. Christian Gluud7

Editorial Group: Cochrane Renal Group

Published Online: 26 JAN 2004

DOI: 10.1002/14651858.CD004681


How to Cite

Penninga L, Webster AC, Egfjord M, Steinbrüchel DA, Gluud C. Antibody immunosuppression for pancreas and kidney-pancreas transplant recipients (Protocol). Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD004681. DOI: 10.1002/14651858.CD004681.

Author Information

  1. 1

    Rigshospitalet, Copenhagen University Hospital, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344,, Copenhagen, Denmark

  2. 2

    University of Sydney, Sydney School of Public Health, Sydney, NSW, Australia

  3. 3

    University of Sydney at Westmead, Centre for Transplant and Renal Research, Westmead Millennium Institute, Westmead, NSW, Australia

  4. 4

    The Children's Hospital at Westmead, Cochrane Renal Group, Centre for Kidney Research, Westmead, NSW, Australia

  5. 5

    Rigshospitalet, Copenhagen University Hospital, Dept 2131, Department of Nephrology, Copenhagen, Denmark

  6. 6

    Rigshospitalet, Copenhagen University Hospital, Dept 2152, Cardiothoracic Surgery, Copenhagen, Denmark

  7. 7

    Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark

*Luit Penninga, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344,, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, DK-2100, Denmark. LP@ctu.rh.dk. luitpenninga@hotmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 26 JAN 2004

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the relative and absolute benefits and harms of different antibody preparations for induction immunosuppression in pancreas and kidney-pancreas transplant recipients. The use of antibody preparations for the treatment of acute rejection will not be part of this review.